Exelixis (EXEL) : On Thursday, The money flowed into the Exelixis (EXEL) stock with an uptick to downtick ratio was recorded at 1.72. Transactions worth $0.31 million were done on upticks, confirming the buying interest in the stock. The outflow of money on downticks stood at $0.18 million. The total money flow into the stock was $0.13 million. The investors are using every small weakness in the stock to accumulate it, as can be seen in the $0.15 million of block transactions on upticks. The total money flow in block trades was $0.15 million. In terms of price action, Exelixis (EXEL) traded down $0.02 during the session at $8.02. Compared to the previous days closing, the stock was down only by -0.25%. For the week, the stock is -1.6%, over previous weeks closing.
The stock has recorded a 20-day Moving Average of 4.74% and the 50-Day Moving Average is 22.09%. Shares have rallied 115.61% from its 1 Year high price. On Jul 11, 2016, the shares registered one year high at $8.28 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $7.33 and the 200 Day Moving Average price is recorded at $5.17.
Exelixis (NASDAQ:EXEL): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $8.11 and $7.97 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $8.26. The buying momentum continued till the end and the stock did not give up its gains. It closed at $8.22, notching a gain of 2.24% for the day. The total traded volume was 6,265,979 . The stock had closed at $8.04 on the previous day.
In an insider trading activity, The Securities and Exchange Commission has divulged in a Form 4 filing that the director of Exelixis, Inc., Willsey Lance had purchased shares worth of $297,600 in a transaction dated on May 9, 2016. A total of 60,000 shares were purchased at a price of $4.96 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).